Stroke Prevention

Intended Format: Grand Rounds – Live/Enduring, Minute-CME/CME Blast, conference satellite, chapter meetings, other

Intended Audience:

• Vascular Neurologist, General Neurologist
• Hospitalist
• Primary Care Physician,
• Pharmacist
• Advanced Practice Providers, e.g. Nurses, Nurse Practitioners, Physician Assistants, Stroke Care Coordinators
• Cardiologist
• Hematologist

Bayer TA Rationale for Educational Support:

Highest priority will be given to programs whose focus is:

• Address unmet need with respect to secondary stroke prevention, highlighting limitations with current standard of care antithrombotic treatment and residual risk of stroke
• Educate on burden of illness of stroke, particularly secondary (following initial stroke or TIA) events
• Establish FXIa inhibition as a new and distinct class of antithrombotic and educate on the mechanism of action of FXIa inhibition
• Review the body of evidence supporting FXI as having a differential role in the coagulation cascade
• Review data set fromOCEANIC-STROKE: including unique efficacy and safety data
• Discuss potential implications of the above studies for incorporation into the current treatment paradigm

Proposal Requirements: :

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning Objectives
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

• Sharma M, Joundi R, Eikelboom J, et al. Factor XIa inhibition with asundexian in acute non-cardioembolic stroke or high-risk transient ischemic attack: primary results of the OCEANIC-STROKE trial. Presented at: International Stroke Conference 2026; February 4-6, 2026; New Orleans, LA. Abstract LB009
• Shoamanesh A, Joundi RA, Dong Q, et al. Qualifying ischemic stroke subtypes and response to asundexian: prespecified secondary analysis of the OCEANIC-STROKE trial. Presented at: International Stroke Conference 2026. February 3-6, 2025; New Orleans, LA. Abstract LB020.
• Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott E Kasner, Jeffrey Saver, Jaime Masjuan, Andrew M Demchuk, Charlotte Cordonnier, Daniel Bereczki, Georgios Tsivgoulis, Roland Veltkamp, Ivan Staikov, Hee-Joon Bae, Bruce C V Campbell, Andrea Zini, I-Hui Lee, Sebastian Ameriso, Martin Kovar, Robert Mikulik, Robin Lemmens, José M Ferro, Thompson Robinson, Hanne Christensen, Serefnur Ozturk, Ronen R Leker, Peter Turcani, Agnieszka Slowik, Pablo Amaya, Fan Kee Hoo, Gian Marco De Marchis, Michael Knoflach, Pillai N Sylaja, Jukka Putaala, Jonathan M Coutinho, H Bart van der Worp, Evija Miglane, Vaidas Matijosaitis, Arne G Lindgren, Gisele Sampaio Silva, Else Charlotte Sandset, Saule Tleubergenovna Turuspekova, Raed A Joundi, Karleen Schulze, Olga Shestakovska, Jennifer Gilbride, Shrikant I Bangdiwala, Lizhen Xu, Eva Muehlhofer, Pablo Colorado, Hardi Mundl, Lars Keller, Ashkan Shoamanesh, OCEANIC-STROKE Investigators, Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention, European Stroke Journal, Volume 11, Issue 1, January 2026, aakaf017, https://doi.org/10.1093/esj/aakaf017
• James C. Fredenburgh, Jeffrey I. Weitz; Factor XI as a Target for New Coagulants; Hamostaseologie 2021; 41(02): 104-110; DOI: 10.1055/a-1384-3715
• Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, Dong Q, Turcani P, Christensen H, Ferro JM, Veltkamp R, Mikulik R, De Marchis GM, Robinson T, Lemmens R, Stepien A, Greisenegger S, Roine R, Csiba L, Khatri P, Coutinho J, Lindgren AG, Demchuk AM, Colorado P, Kirsch B, Neumann C, Heenan L, Xu L, Connolly SJ, Hart RG; PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022 Sep 24;400(10357):997-1007. doi: 10.1016/S0140-6736(22)01588-4. Epub 2022 Sep 2. PMID: 36063821.
• Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, Legnazzi M, Mauro MS, Mazzone PM, Occhipinti G, Rochira C, Scalia L, Capodanno D. Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation. 2023 Mar 14;147(11):897-913. doi: 10.1161/CIRCULATIONAHA.122.062353. Epub 2023 Mar 13. PMID: 36913497.
• GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3. PMID: 34487721; PMCID: PMC8443449.
• Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association [published correction appears in Stroke. 2021 Jul;52(7):e483-e484]. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375